Cdk4 Antibody (DCS-35): sc-23896

Cdk4 Antibody (DCS-35) is a mouse monoclonal IgG1 kappa light chain antibody engineered to detect Cyclin-dependent kinase 4 (Cdk4), also known as CDC2-like kinase 4, across mouse, rat, and human species. anti-Cdk4 antibody (DCS-35) targets an epitope within the first 20 amino acids of the full-length recombinant human Cdk4 protein, ensuring effective recognition in applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). Cdk4 is a vital member of the cyclin-dependent kinase family, playing a crucial role in regulating cell cycle progression by partnering with D-type cyclins to control cell growth during the G1 phase. The function of Cdk4 is essential for the phosphorylation of key substrates that drive the cell cycle forward, making Cdk4 a significant focus in cancer research and studies of cellular proliferation. The activity of Cdk4 is modulated through interaction with cyclins, which enhance kinase activity, and inhibitors like p16, which suppress function. Additionally, the activation of Cdk4-cyclin complexes involves phosphorylation by Cdk-activating proteins (CAK), highlighting the sophisticated regulatory mechanisms governing cell cycle progression. Cdk4 (DCS-35) monoclonal antibody is available in both non-conjugated form and a variety of conjugated formats, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. By providing reliable detection of Cdk4 across multiple species and applications, Cdk4 (DCS-35) antibody serves as an invaluable tool for researchers investigating cell cycle dynamics and related signaling pathways.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cdk4 Antibody (DCS-35) References:

1. PCTAIRE-1 and PCTAIRE-3, two members of a novel cdc2/CDC28-related protein kinase gene family.  |  Okuda, T., et al. 1992. Oncogene. 7: 2249-58. PMID: 1437147
2. Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.  |  Wu, X., et al. 2021. Nat Cancer. 2: 429-443. PMID: 34568836
3. Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors.  |  Cai, Z., et al. 2023. Sci China Life Sci. 66: 94-109. PMID: 35982377
4. CDK4: a master regulator of the cell cycle and its role in cancer.  |  Baker, SJ., et al. 2022. Genes Cancer. 13: 21-45. PMID: 36051751
5. The cell cycle kinases.  |  Pines, J. 1994. Semin Cancer Biol. 5: 305-13. PMID: 7803767
6. Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase.  |  Matsuoka, M., et al. 1994. Mol Cell Biol. 14: 7265-75. PMID: 7935441
7. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase.  |  Kato, JY., et al. 1994. Mol Cell Biol. 14: 2713-21. PMID: 8139570
8. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.  |  Serrano, M., et al. 1993. Nature. 366: 704-7. PMID: 8259215
9. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer.  |  MacLachlan, TK., et al. 1995. Crit Rev Eukaryot Gene Expr. 5: 127-56. PMID: 8845581
10. Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma.  |  Siebert, R., et al. 1996. Leuk Lymphoma. 23: 505-20. PMID: 9031081
11. Current concepts in neuro-oncology: the cell cycle--a review.  |  Dirks, PB. and Rutka, JT. 1997. Neurosurgery. 40: 1000-13; discussion 1013-5. PMID: 9149259
12. Identification of CDK4 sequences involved in cyclin D1 and p16 binding.  |  Coleman, KG., et al. 1997. J Biol Chem. 272: 18869-74. PMID: 9228064

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-Cdk4 Antibody (DCS-35) has 208 citations in a variety of scientific publications.

Primary antibodies like Anti-Cdk4 Antibody (DCS-35) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

Cdk4 Antibody (DCS-35) Specifications

Alternate Product Name: Cdk4

Product Clone Name: DCS-35

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 1-20

Epitope Target: Cdk4

Epitope Species: human

Product Reactivity/Detection: Cdk4

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 208 citations in various scientific publications

Available Conjugates/Forms for Cdk4 Antibody (DCS-35): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin